Why you should invest in NeutriSciIt's not for the upcoming Nu.THC and Nu.CBD tabs (which are exciting), but for the other compound at the heart of the company - Pterostilbene.
I'll admit when I first invested in NU in late January it was because the company looked attractive at current market cap and I believed the hype surrounding CBD/THC products would easily lead to new all-time highs for this stock. I still believe that to be the case but the more homework I do on this company the more confident I've become.
After having done some considerable due diligence around the key ingredient in NeutriSci's NeuEnergy and upcoming THC/CBD products - Pterostilbene - I've recently doubled my position. The improved bioavailability and numerous health benefits it offers, combined with the recent news on their patent regarding combining Pterostilbene with cannabinoids, convinces me we have an exciting opportunity here to invest in NeutriSci at such low market cap.
For those who haven't researched Pterostilbene, take a few minutes to google it or read the incredibly informative article below that helps describe some of the findings from hundreds of scientific publications over the last few years.
https://www.superfoodly.com/pterostilbene-supplement-benefits-longevity-miracle-or-hoax/
A few highlights of Pterostilbene:
-natural antioxidant found in many blueberries, grapes, almonds and other plants
-high bioavailbility with 7 fold longer half-life than resveratrol
-highly studied for it's anti-cancer properties
-may reduce blood pressure, stimulate weight loss, and repair damage to cells
-potentially anti-aging effects
-the downsides of Pterostilbene are very limited and not entirely understood at this point, but the research shows incredible promise
The major challenge for cannabinoid drug delivery is the absorption in the gut/low bioavailability. If Pterostilbene proves effective to increase CBD delivery (which is the goal of the Scientus Pharma collaboration), the value of this company should skyrocket and we could see more pharma investment. I'm convinced that NeutriSci understands this as a critical component of their success, hence why they've filed for patent on combining Pterstilbene with cannabinoids. I was surprised that this news didn't cause a spike in the share price. Perhaps this is because not everyone understands the challenges around creating a CBD/THC in controlled dose form.
Hopefully everyone does their due diligence and the with the help of Genie Bouchard the word will spread quickly about NU. The distribution channel already established by NeutriSci is incredibly impressive. I'm confident we have a winner and looking forward to what the future will bring for shareholders. GLTA